Finance

Lists
007570:KRX
Ilyang Pharmaceutical Co Ltd
â‚©8,370.00
+0.12%
(+10.00) 1D
Sep 4, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 007570...
Open
â‚©8,500
High
â‚©8,500
Low
â‚©8,180
Mkt. cap
163.27B
Avg. vol.
23.45K
Volume
5.70K
Dividend
1.85%
Quarterly dividend
â‚©39
Ex-dividend date
Dec 27, 2023
P/E ratio
7.26
52-wk high
â‚©16,240
52-wk low
â‚©7,290
EPS
â‚©1,153
Shares outstanding
19.09M
No. of employees
666
Open
â‚©8,500
High
â‚©8,500
Low
â‚©8,180
Mkt. cap
163.27B
Avg. vol.
23.45K
Volume
5.70K
Dividend
1.85%
Quarterly dividend
â‚©39
Ex-dividend date
Dec 27, 2023
P/E ratio
7.26
52-wk high
â‚©16,240
52-wk low
â‚©7,290
EPS
â‚©1,153
Shares outstanding
19.09M
No. of employees
666
About Ilyang Pharmaceutical Co Ltd
CEOKim Dong-yeon
Employees666
FoundedJul 1, 1946
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
68.83B
78.91B
65.07B
65.14B
Cost of goods sold
41.32B
45.42B
40.63B
40.74B
Cost of revenue
41.32B
45.42B
40.63B
40.74B
Research and development expenses
7.01B
7.00B
8.87B
5.94B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19.76B
24.92B
22.29B
22.34B
Operating expense
27.66B
32.93B
31.82B
31.17B
Total operating expenses
68.98B
78.35B
72.44B
71.91B
Operating income
-157.75M
565.93M
-7.37B
-6.77B
Other non operating income
11.87B
-681.30M
24.70B
2.24B
EBT including unusual items
11.42B
-1.72B
17.95B
-5.08B
EBT excluding unusual items
11.35B
-1.72B
17.62B
-5.06B
Income tax expense
3.04B
3.92B
983.97M
-2.74B
Effective tax rate
26.58%
-227.04%
5.48%
53.89%
Other operating expenses
639.84M
573.32M
453.35M
433.71M
Net income
8.44B
-5.65B
16.80B
-2.29B
Net profit margin
12.26%
-7.16%
25.81%
-3.52%
Earnings per share
-
-
-
-
Interest and investment income
-
184.97M
140.72M
144.16M
Interest expense
-
-738.07M
-711.18M
-702.63M
Net interest expenses
-
-553.10M
-570.46M
-558.47M
Depreciation and amortization charges
212.18M
210.49M
211.82M
220.64M
EBITDA
1.93B
2.65B
-5.30B
-4.54B
Gain or loss from assets sale
-71.72M
6.86K
-
31.87M
AI content may include mistakes. Learn more
Google apps